Acalabrutinib is an antidepressant that is prescribed to cancer patients with no known cause-or risk for an attack. In a phase II clinical trial, it was shown to be effective in preventing recurrences in patients who experienced a treatment-induced depression. Data also indicated that the long-term safety of this drug was favorable. The results were published in the July issue of JAMA.
In recent years, it has been discovered that acalabrutinib increases collagen-induced platelet aggregation in patients with a family history of inflammatory diseases. These patients had higher than average rates of major inflammatory diseases, such as leukaemia, lymphomas, and multiple sclerosis. No significant between-study variation was noted in either the frequency or the intensity of occurrence of depression, mood swings, or fatigue. No other side effects of this antidepressant were noted.
Like many an antidepressant, acalabrutinib like Regorafenib has some negative side effects. Some patients experienced nausea, vomiting, constipation, taste disturbances, and increased appetite. Less common but noted side effects were increase in the frequency of diarrhea and increased thirst. Most patients with allergic reactions to adenosine became intolerant to acalabrutinib within the first week of therapy. In most patients, these symptoms improved over the next two weeks.
The recent study of this antidepressant showed a lower incidence of serious adverse events in patients who had reported at least one significant negative event (e.g., suicide, hospitalization, or physical illness). However, there was a higher frequency of discontinuation reactions among individuals with a family history of acute coronary syndromes.
Other recent studies showed similar or fewer occurrences of adverse events in patients taking antidepressants (e.g., tricyclic antidepressants) that contained aniracetamol. Also, a recent study showed no significant difference between the use of antidepressants and lamotrigine in patients who have at least one mild to moderate degree of acid reflux.
Although this does not necessarily indicate that there are no drug interactions between antacids and acid reflux medications, the lack of significant adverse effects in the recent studies is encouraging.
Another study of a novel antacids containing aloe vera showed a lower toxic profile in patients who tolerated acalabrutinib compared to patients who tolerated gemcitabine. Gemcitaben is the primary antacids used in the treatment of acid reflux in patients with Helicobacter pylori infection. This medication has been shown to cause significant adverse events in patients with ulcers, liver disease, and kidney disease.
Patients with advanced liver disease and ulcers may not be able to tolerate gemcitabine. Studies suggest that patients with severe peptic ulcers should avoid the use of antacids containing aloe vera and that therapy for these patients should focus on acid-base medications.
Studies suggest that some patients who respond to the effects of antacids may have difficulty in maintaining a consistent acalabrutinib dosage and may need to increase the drug dose during the acute exacerbation phase. This increase in dosage is believed to be associated with increased mortality.
Although this is the case, the decreased mortality rate observed with this combination of antacids is not consistent with the decreased morbidity seen with other studies. The decreased morbidity with acalabrutinib in the aspirin group may be due to the lower levels of calcium in the bloodstream of these patients.
Other studies have shown that patients who were treated with acetazolamide failed to tolerate the drug well and were more likely to experience serious side effects. These side effects included restlessness, nausea, vomiting, peptic ulcer, vision problems, seizures, allergic reactions, and changes in heart rate and blood pressure. You can contact us for more information.